What’s new in musculoskeletal oncology

We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially in challenging anatomical locations, such as t...

Full description

Saved in:
Bibliographic Details
Published in:BMC musculoskeletal disorders 2021-08, Vol.22 (1), p.1-704, Article 704
Main Authors: Errani, Costantino, Mavrogenis, Andreas F, Tsukamoto, Shinji
Format: Article
Language:English
Subjects:
Bone cancer
Bone marrow
Bone sarcomas
Bone surgery
Bone tumors
C-reactive protein
Cancer
Care and treatment
Chemotherapy
Curettage
Cysts
Embolization
FDA approval
Fractures
Life span
Long bone
Medical prognosis
Metastases
Metastasis
Metastatic bone tumor
Muscle tissue tumors
Muscular system
Musculoskeletal diseases
Musculoskeletal tumors
Oncology
Oncology, Experimental
Orthopedic surgery
Patients
Pelvis
Prosthetics
Radiation therapy
Review
Sacrum
Sarcoma
Soft tissue sarcomas
Soft tissue tumors
Surgery
Surgical outcomes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c540t-63d2ee9fdc728ef80de2f8f5e4e35effcad510d0ac236d01b605ca427529ae5a3
cites cdi_FETCH-LOGICAL-c540t-63d2ee9fdc728ef80de2f8f5e4e35effcad510d0ac236d01b605ca427529ae5a3
container_end_page 704
container_issue 1
container_start_page 1
container_title BMC musculoskeletal disorders
container_volume 22
creator Errani, Costantino
Mavrogenis, Andreas F
Tsukamoto, Shinji
description We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially in challenging anatomical locations, such as the sacrum and pelvis. Regarding the treatment of giant cell tumor of bone, recent studies have suggested that denosumab administration is related to a higher local recurrence rate following curettage, but a lower local recurrence rate following en bloc resection. In addition, there was no difference in the local recurrence rate at five years after surgery between short-term and long-term denosumab therapy. With regard to soft tissue tumors, percutaneous cryoablation appears to be a new treatment option for extra-abdominal desmoid tumors, with encouraging results. Regarding soft tissue sarcomas, a negative surgical margin of
doi_str_mv 10.1186/s12891-021-04590-1
format article
fullrecord <record><control><sourceid>gale_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_6d97dd30ac25484c8a55dc96e84d35e0</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A675243025</galeid><doaj_id>oai_doaj_org_article_6d97dd30ac25484c8a55dc96e84d35e0</doaj_id><sourcerecordid>A675243025</sourcerecordid><originalsourceid>FETCH-LOGICAL-c540t-63d2ee9fdc728ef80de2f8f5e4e35effcad510d0ac236d01b605ca427529ae5a3</originalsourceid><addsrcrecordid>eNptks1qVDEUx4MotlZfwNWAm25uzfdNNkIpfhQKbhSXIU1Ophlzk5rcq3Tna_h6PomZmaKOSAgJJ__zO5yTP0LPCT4jRMmXjVClyYBp31xoPJAH6JjwkQyUj_zhX_cj9KS1DcZkVEw_RkeMc8zZqI_R6acbO__8_qOtMnxbxbyaluaWVNpnSDDbtCrZlVTWd0_Ro2BTg2f35wn6-Ob1h4t3w9X7t5cX51eDExzPg2SeAujg3UgVBIU90KCCAA5MQAjOekGwx9ZRJj0m1xILZzkdBdUWhGUn6HLP9cVuzG2Nk613pthodoFS18bWOboERno9es-2LMEVd8oK4Z2WoLjvxXBnvdqzbpfrCbyDPFebDqCHLznemHX5ahSTmnPeAaf3gFq-LNBmM8XmICWboSzNUCGpIKNgsktf_CPdlKXmPqqdqv-PJPqPam17AzGH0uu6LdScyz4DzjAVXXX2H1VfHqboSoYQe_wgge4TXC2tVQi_eyTYbL1i9l4x3Stm5xVD2C_p3688</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2562459619</pqid></control><display><type>article</type><title>What’s new in musculoskeletal oncology</title><source>Publicly Available Content Database</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Errani, Costantino ; Mavrogenis, Andreas F ; Tsukamoto, Shinji</creator><creatorcontrib>Errani, Costantino ; Mavrogenis, Andreas F ; Tsukamoto, Shinji</creatorcontrib><description>We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially in challenging anatomical locations, such as the sacrum and pelvis. Regarding the treatment of giant cell tumor of bone, recent studies have suggested that denosumab administration is related to a higher local recurrence rate following curettage, but a lower local recurrence rate following en bloc resection. In addition, there was no difference in the local recurrence rate at five years after surgery between short-term and long-term denosumab therapy. With regard to soft tissue tumors, percutaneous cryoablation appears to be a new treatment option for extra-abdominal desmoid tumors, with encouraging results. Regarding soft tissue sarcomas, a negative surgical margin of &lt; 1 mm is sufficient to control local recurrence. Pexidartinib seems to be a promising systemic therapy for the treatment of tenosynovial giant cell tumors for which surgery is not expected to improve the function of the affected limb. Finally, the life expectancy of patients is the most important factor in determining the optimal surgical procedure for patients with impending or pathological fractures of the long bone due to metastatic bone tumors. Elevated C-reactive protein level was found to be an independent poor prognostic factor at 1 year after surgery for long bone metastases.</description><identifier>ISSN: 1471-2474</identifier><identifier>EISSN: 1471-2474</identifier><identifier>DOI: 10.1186/s12891-021-04590-1</identifier><identifier>PMID: 34404379</identifier><language>eng</language><publisher>London: BioMed Central Ltd</publisher><subject>Bone cancer ; Bone marrow ; Bone sarcomas ; Bone surgery ; Bone tumors ; C-reactive protein ; Cancer ; Care and treatment ; Chemotherapy ; Curettage ; Cysts ; Embolization ; FDA approval ; Fractures ; Life span ; Long bone ; Medical prognosis ; Metastases ; Metastasis ; Metastatic bone tumor ; Muscle tissue tumors ; Muscular system ; Musculoskeletal diseases ; Musculoskeletal tumors ; Oncology ; Oncology, Experimental ; Orthopedic surgery ; Patients ; Pelvis ; Prosthetics ; Radiation therapy ; Review ; Sacrum ; Sarcoma ; Soft tissue sarcomas ; Soft tissue tumors ; Surgery ; Surgical outcomes ; Tumors</subject><ispartof>BMC musculoskeletal disorders, 2021-08, Vol.22 (1), p.1-704, Article 704</ispartof><rights>COPYRIGHT 2021 BioMed Central Ltd.</rights><rights>2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c540t-63d2ee9fdc728ef80de2f8f5e4e35effcad510d0ac236d01b605ca427529ae5a3</citedby><cites>FETCH-LOGICAL-c540t-63d2ee9fdc728ef80de2f8f5e4e35effcad510d0ac236d01b605ca427529ae5a3</cites><orcidid>0000-0002-4504-2867</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369444/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2562459619?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,38516,43895,44590,53791,53793</link.rule.ids></links><search><creatorcontrib>Errani, Costantino</creatorcontrib><creatorcontrib>Mavrogenis, Andreas F</creatorcontrib><creatorcontrib>Tsukamoto, Shinji</creatorcontrib><title>What’s new in musculoskeletal oncology</title><title>BMC musculoskeletal disorders</title><description>We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially in challenging anatomical locations, such as the sacrum and pelvis. Regarding the treatment of giant cell tumor of bone, recent studies have suggested that denosumab administration is related to a higher local recurrence rate following curettage, but a lower local recurrence rate following en bloc resection. In addition, there was no difference in the local recurrence rate at five years after surgery between short-term and long-term denosumab therapy. With regard to soft tissue tumors, percutaneous cryoablation appears to be a new treatment option for extra-abdominal desmoid tumors, with encouraging results. Regarding soft tissue sarcomas, a negative surgical margin of &lt; 1 mm is sufficient to control local recurrence. Pexidartinib seems to be a promising systemic therapy for the treatment of tenosynovial giant cell tumors for which surgery is not expected to improve the function of the affected limb. Finally, the life expectancy of patients is the most important factor in determining the optimal surgical procedure for patients with impending or pathological fractures of the long bone due to metastatic bone tumors. Elevated C-reactive protein level was found to be an independent poor prognostic factor at 1 year after surgery for long bone metastases.</description><subject>Bone cancer</subject><subject>Bone marrow</subject><subject>Bone sarcomas</subject><subject>Bone surgery</subject><subject>Bone tumors</subject><subject>C-reactive protein</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Curettage</subject><subject>Cysts</subject><subject>Embolization</subject><subject>FDA approval</subject><subject>Fractures</subject><subject>Life span</subject><subject>Long bone</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Metastatic bone tumor</subject><subject>Muscle tissue tumors</subject><subject>Muscular system</subject><subject>Musculoskeletal diseases</subject><subject>Musculoskeletal tumors</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Orthopedic surgery</subject><subject>Patients</subject><subject>Pelvis</subject><subject>Prosthetics</subject><subject>Radiation therapy</subject><subject>Review</subject><subject>Sacrum</subject><subject>Sarcoma</subject><subject>Soft tissue sarcomas</subject><subject>Soft tissue tumors</subject><subject>Surgery</subject><subject>Surgical outcomes</subject><subject>Tumors</subject><issn>1471-2474</issn><issn>1471-2474</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNptks1qVDEUx4MotlZfwNWAm25uzfdNNkIpfhQKbhSXIU1Ophlzk5rcq3Tna_h6PomZmaKOSAgJJ__zO5yTP0LPCT4jRMmXjVClyYBp31xoPJAH6JjwkQyUj_zhX_cj9KS1DcZkVEw_RkeMc8zZqI_R6acbO__8_qOtMnxbxbyaluaWVNpnSDDbtCrZlVTWd0_Ro2BTg2f35wn6-Ob1h4t3w9X7t5cX51eDExzPg2SeAujg3UgVBIU90KCCAA5MQAjOekGwx9ZRJj0m1xILZzkdBdUWhGUn6HLP9cVuzG2Nk613pthodoFS18bWOboERno9es-2LMEVd8oK4Z2WoLjvxXBnvdqzbpfrCbyDPFebDqCHLznemHX5ahSTmnPeAaf3gFq-LNBmM8XmICWboSzNUCGpIKNgsktf_CPdlKXmPqqdqv-PJPqPam17AzGH0uu6LdScyz4DzjAVXXX2H1VfHqboSoYQe_wgge4TXC2tVQi_eyTYbL1i9l4x3Stm5xVD2C_p3688</recordid><startdate>20210817</startdate><enddate>20210817</enddate><creator>Errani, Costantino</creator><creator>Mavrogenis, Andreas F</creator><creator>Tsukamoto, Shinji</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><general>BMC</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>COVID</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-4504-2867</orcidid></search><sort><creationdate>20210817</creationdate><title>What’s new in musculoskeletal oncology</title><author>Errani, Costantino ; Mavrogenis, Andreas F ; Tsukamoto, Shinji</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c540t-63d2ee9fdc728ef80de2f8f5e4e35effcad510d0ac236d01b605ca427529ae5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bone cancer</topic><topic>Bone marrow</topic><topic>Bone sarcomas</topic><topic>Bone surgery</topic><topic>Bone tumors</topic><topic>C-reactive protein</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Curettage</topic><topic>Cysts</topic><topic>Embolization</topic><topic>FDA approval</topic><topic>Fractures</topic><topic>Life span</topic><topic>Long bone</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Metastatic bone tumor</topic><topic>Muscle tissue tumors</topic><topic>Muscular system</topic><topic>Musculoskeletal diseases</topic><topic>Musculoskeletal tumors</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Orthopedic surgery</topic><topic>Patients</topic><topic>Pelvis</topic><topic>Prosthetics</topic><topic>Radiation therapy</topic><topic>Review</topic><topic>Sacrum</topic><topic>Sarcoma</topic><topic>Soft tissue sarcomas</topic><topic>Soft tissue tumors</topic><topic>Surgery</topic><topic>Surgical outcomes</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Errani, Costantino</creatorcontrib><creatorcontrib>Mavrogenis, Andreas F</creatorcontrib><creatorcontrib>Tsukamoto, Shinji</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>BMC musculoskeletal disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Errani, Costantino</au><au>Mavrogenis, Andreas F</au><au>Tsukamoto, Shinji</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>What’s new in musculoskeletal oncology</atitle><jtitle>BMC musculoskeletal disorders</jtitle><date>2021-08-17</date><risdate>2021</risdate><volume>22</volume><issue>1</issue><spage>1</spage><epage>704</epage><pages>1-704</pages><artnum>704</artnum><issn>1471-2474</issn><eissn>1471-2474</eissn><abstract>We reviewed the recent literature related to primary musculoskeletal tumors and metastatic bone tumors. With regard to primary bone tumors, computer navigation systems and three-dimensional-printed prostheses seem to be new treatment options, especially in challenging anatomical locations, such as the sacrum and pelvis. Regarding the treatment of giant cell tumor of bone, recent studies have suggested that denosumab administration is related to a higher local recurrence rate following curettage, but a lower local recurrence rate following en bloc resection. In addition, there was no difference in the local recurrence rate at five years after surgery between short-term and long-term denosumab therapy. With regard to soft tissue tumors, percutaneous cryoablation appears to be a new treatment option for extra-abdominal desmoid tumors, with encouraging results. Regarding soft tissue sarcomas, a negative surgical margin of &lt; 1 mm is sufficient to control local recurrence. Pexidartinib seems to be a promising systemic therapy for the treatment of tenosynovial giant cell tumors for which surgery is not expected to improve the function of the affected limb. Finally, the life expectancy of patients is the most important factor in determining the optimal surgical procedure for patients with impending or pathological fractures of the long bone due to metastatic bone tumors. Elevated C-reactive protein level was found to be an independent poor prognostic factor at 1 year after surgery for long bone metastases.</abstract><cop>London</cop><pub>BioMed Central Ltd</pub><pmid>34404379</pmid><doi>10.1186/s12891-021-04590-1</doi><orcidid>https://orcid.org/0000-0002-4504-2867</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1471-2474
ispartof BMC musculoskeletal disorders, 2021-08, Vol.22 (1), p.1-704, Article 704
issn 1471-2474
1471-2474
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_6d97dd30ac25484c8a55dc96e84d35e0
source Publicly Available Content Database; PubMed Central; Coronavirus Research Database
subjects Bone cancer
Bone marrow
Bone sarcomas
Bone surgery
Bone tumors
C-reactive protein
Cancer
Care and treatment
Chemotherapy
Curettage
Cysts
Embolization
FDA approval
Fractures
Life span
Long bone
Medical prognosis
Metastases
Metastasis
Metastatic bone tumor
Muscle tissue tumors
Muscular system
Musculoskeletal diseases
Musculoskeletal tumors
Oncology
Oncology, Experimental
Orthopedic surgery
Patients
Pelvis
Prosthetics
Radiation therapy
Review
Sacrum
Sarcoma
Soft tissue sarcomas
Soft tissue tumors
Surgery
Surgical outcomes
Tumors
title What’s new in musculoskeletal oncology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T16%3A44%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=What%E2%80%99s%20new%20in%20musculoskeletal%20oncology&rft.jtitle=BMC%20musculoskeletal%20disorders&rft.au=Errani,%20Costantino&rft.date=2021-08-17&rft.volume=22&rft.issue=1&rft.spage=1&rft.epage=704&rft.pages=1-704&rft.artnum=704&rft.issn=1471-2474&rft.eissn=1471-2474&rft_id=info:doi/10.1186/s12891-021-04590-1&rft_dat=%3Cgale_doaj_%3EA675243025%3C/gale_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c540t-63d2ee9fdc728ef80de2f8f5e4e35effcad510d0ac236d01b605ca427529ae5a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2562459619&rft_id=info:pmid/34404379&rft_galeid=A675243025&rfr_iscdi=true